| 2025/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 21,512,920 | -12.38% | 30,317,288 | 36,418,770 | 37,834,859 | 41,053,584 | |
| 減：營業總成本 | 21,460,284 | -11.96% | 30,630,058 | 36,503,984 | 37,782,459 | 40,327,347 | |
| 其中:營業成本 | 19,531,505 | -11.71% | 27,444,707 | 32,865,445 | 34,045,035 | 36,655,494 | |
| 財務費用 | 449,888 | -15.90% | 806,282 | 943,621 | 905,212 | 807,226 | |
| 資產減值損失 | 11,221 | 1,092.45% | (518,749) | (962,355) | (550,406) | (197,520) | |
| 公允價值變動收益 | 141 | -98.59% | 6,384 | 17,752 | 56,847 | 37,706 | |
| 投資收益 | 91,633 | -- | 11,147 | (45,418) | (143,505) | 37,329 | |
| 其中：對聯營企業和合營企業的投資收益 | 358 | 2,653.85% | 4,318 | (26,996) | (106,917) | 46,675 | |
| 營業利潤 | 165,529 | -38.00% | (1,062,938) | (1,468,030) | (854,588) | 561,017 | |
| 利潤總額 | 167,901 | -37.55% | (1,081,694) | (1,458,474) | (853,160) | 576,310 | |
| 減：所得稅費用 | 99,660 | -30.32% | 85,617 | 260,559 | 138,290 | 318,443 | |
| 淨利潤 | 68,240 | -45.77% | (1,167,311) | (1,719,033) | (991,450) | 257,868 | |
| 減：非控股權益 | 42,537 | -46.58% | 26,104 | (29,088) | 35,519 | 164,572 | |
| 股東淨利潤 | 25,703 | -44.39% | (1,193,415) | (1,689,945) | (1,026,969) | 93,295 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.010 | -44.44% | -0.454 | -0.642 | -0.391 | 0.036 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | 0.693 | -39.95% | 0.682 | 1.092 | 1.705 | 2.117 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
000078 海王生物
按盤價 
3.580 -0.030 (-0.83%)
3.580 -0.030 (-0.83%)| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 03/04/2026 16:30 |
